Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments like minoxidil, finasteride, dutasteride, and RU58841. Users stress early prevention and discuss challenges with different hair loss patterns.

The user shared their positive experience with hair regrowth using finasteride, oral and topical minoxidil, and keto shampoo, noting gradual improvement and no side effects. They emphasized the importance of starting treatment early and maintaining consistency and patience.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

Doctors recommend starting with minoxidil for hair loss due to its lower risk of side effects compared to finasteride. Some believe finasteride should be used early to address the root cause, but a conservative approach is preferred by medical professionals.

The user started using oral finasteride and minoxidil a year ago and is questioning if there's improvement in hair regrowth. Responses indicate noticeable improvement and suggest the user caught hair loss early, likely returning to their peak hair condition.

The user shared a 5-month update on hair regrowth using Minoxidil twice daily and Finasteride every other day, noting significant progress and initial shedding. The user started treatment at age 33 after experiencing hair loss since their early 20s.

A 24-year-old male is using topical Minoxidil and Finasteride, along with microneedling, to address hair loss and is seeing some improvement, though it's early in the treatment process. The user is advised to continue the regimen for at least 12 months for a clearer assessment, with some recovery possibly due to resolving telogen effluvium from a previous caloric deficit.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

The conversation discusses hair loss treatments, specifically mentioning pyrilutamide, minoxidil, and finasteride. The consensus suggests starting treatment early, with finasteride being a preferred option.

A user shares optimism about combating male pattern baldness using oral and topical minoxidil, highlighting the advancements in treatments available today. Another user agrees, noting that early treatment can yield good results, and mentions the availability of affordable hair transplants.

A young person regrets not starting hair loss treatments like minoxidil and finasteride earlier, leading to significant balding by age 19. They discuss the importance of early intervention and the impact of societal perceptions on those experiencing hair loss.

Young men often lack awareness of hair loss treatments like finasteride and minoxidil, causing stress and anxiety. There is a need for increased awareness and early screening to address the psychological effects of hair loss.

A user is concerned about receding hairlines and considers using finasteride and minoxidil but is hesitant due to potential side effects. Others advise starting treatment early to prevent further hair loss, emphasizing that finasteride is generally safe and effective for prevention.

The conversation is about a user taking 0.5 mg of dutasteride daily for a month to address hair loss. Users suggest that it's too early to see results and recommend adding minoxidil and waiting longer for noticeable changes.

A 25-year-old male has been using 1mg finasteride and 5% minoxidil for 10 months. Users comment that his hair looks healthy and thick, suggesting early treatment was beneficial.

The user shared a two-year update on hair loss treatment using oral minoxidil, finasteride, and microneedling, noting significant progress after starting oral treatments and microneedling. They began treatment in early 2023 after noticing hair loss in late 2021.

A 40-year-old male has been using 5% minoxidil foam, 1mg finasteride, and a derma roller weekly for 2.5 months to treat hair loss. He is seeking feedback on whether the treatment is showing progress or if it's too early to tell.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

Hair loss treatments like finasteride, dutasteride, and minoxidil are discussed, with differing views on when to begin treatment. Some suggest early use, while others warn of hormonal side effects from starting too young.

A trans man shared his 5-month progress using finasteride and minoxidil for temple regrowth, noting slow but steady results. Despite some negative comments, he received support and encouragement from others, with advice to start treatment early for best results.

OP used 0.4 mg Dutasteride and 2 mg Minoxidil for 7 months, seeing significant hair density improvement without a noticeable shedding phase. OP takes a combined oral pill from Musely and is in their early forties.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

Derek has maintained his hair for over a decade using dutasteride, keto shampoo, and previously minoxidil, despite early hair loss and family history of baldness. Other users discuss their own hair loss treatments, including combinations of oral minoxidil, finasteride, dutasteride, RU58841, nizoral, microneedling, and low-level laser therapy.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

An 18-year-old is maintaining a stable hairline using Minoxidil, topical finasteride (Fynzur), and Dermastamp, and is considering adding oral finasteride for prevention. They seek advice on whether starting oral finasteride early is necessary given their family history and current regimen.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

Redensyl is a plant-based treatment that may support hair regrowth by reactivating dormant follicles and improving hair density, especially in early-stage thinning. It is not a miracle cure and results vary; it is less proven than Minoxidil or Finasteride and may cause scalp irritation.